Form 4: Eli Lilly Director Acquires Stock Units

Eli Lilly Director Juan R. Luciano acquired stock units valued at approximately $988.09 per share, totaling over $16,000, as part of a deferred compensation plan.

Summary

• Juan R. Luciano, a Director at Eli Lilly & Co. (LLY), acquired 16.109 shares of common stock in the form of stock units.
• These shares were acquired on May 18, 2026, at a price of $988.09 per share, with a total value of $16,109.
• The acquisition was made under the Lilly Directors' Deferral Plan, where shares are deferred in lieu of cash compensation.
• These stock units will be settled in shares of common stock upon the reporting person's separation from service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard compensation and retention mechanism for a director, indicating continued commitment rather than a significant new development.

Positives

• Director Luciano's acquisition of stock units indicates continued investment and confidence in the company.
• The acquisition is part of a structured deferred compensation plan, suggesting a long-term incentive alignment for management.

Future Outlook

The acquired stock units will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the acquisition of stock or stock units by directors, are often viewed as a signal of management's confidence in the company's future prospects. This type of transaction is common within the pharmaceutical industry as a method of executive and director compensation and retention.

Stakeholder Impact

• Shareholders: The transaction reflects a standard compensation practice, with no immediate direct impact on share price, but can be interpreted as a positive signal of insider confidence.

Next Steps

• Settlement of stock units in shares of common stock upon reporting person's separation from service.

Key Dates

Keywords

Eli Lilly, LLY, Form 4, Insider Trading, Stock Units, Deferred Compensation, Director Compensation, SEC Filing